|Education||BS, California State Polytechnic University|
Breast cancer can be viewed as a progressive disease where patients develop atypical ductal hyperplasia (ADH), ductal carcinoma is situ (DCIS) and eventually invasive ductal carcinoma (IDC). A subset of patients who develop DCIS have disease that do not progress to IDC. Since we do not have a tool that allows us to distinguish patients that progress versus those who don’t, the patients who will not develop IDC receive the same intense therapy as their counterparts who do. My research aims to look for genetic, epigenetic and gene expression differences between these subsets of patients using different microarray platforms to develop biomarkers that will allow us to better diagnose and treat patients.